1368 results about "Isoelectric point" patented technology

The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.

The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

An aspect of the present invention relates to a method of manufacturing hexagonal ferrite magnetic powder. The method of manufacturing hexagonal ferrite magnetic powder comprises wet processing hexagonal ferrite magnetic particles obtained following acid treatment in a water-based solvent to prepare an aqueous magnetic liquid satisfying relation (1) relative to an isoelectric point of the hexagonal ferrite magnetic particles: pH0−pH*≧2.5, wherein, pH0 denotes the isoelectric point of the hexagonal ferrite magnetic particles and pH* denotes a pH of the aqueous magnetic liquid, which is a value of equal to or greater than 2.0, adding a surface-modifying agent comprising an alkyl group and a functional group that becomes an anionic group in the aqueous magnetic liquid to the aqueous magnetic liquid to subject the hexagonal ferrite magnetic particles to a surface-modifying treatment, and removing the water-based solvent following the surface-modifying treatment to obtain hexagonal ferrite magnetic particles.

The invention discloses an enteric-solubility multilayer encysted bacterium microcapsule and making method in the biological agent technical domain, which is characterized by the following: adopting sodium alginate, calcium chloride and chitose as clad material of microcapsule; making lactic acid bacteria or bifidobacteria as core-clad material; proceeding ionic exchange for sodium alginate and calcium chloride; forming second clad on the surface of calcium alginate through different isoelectric points of calcium alginate and chitose; freezing at low temperature to obtain the product.

Problems to be Solved: The present invention provides a simpler and less expensive method for purifying physiologically active proteins, especially antibodies, which can ensure removal of impurities such as DNA contaminants and viruses, and which can minimize a loss of physiologically active proteins. Means for Solving the Problems: A method for removing impurities in a physiologically active protein-containing sample, which comprises the following steps: 1) allowing the physiologically active protein-containing sample to be converted into an aqueous solution of low conductivity at a pH below the isoelectric point of the physiologically active protein; and 2) removing the resulting particles.

The present invention relates to a process for making a titanium dioxide pigment having consisting of titanium dioxide and single layer of inorganic surface treatment consisting of aluminum phosphate wherein the pigment is characterized by and isoelectric point which is greater than pH 6 and a negative zeta potential of at a pH of 7.5 or more.

The, present invention provides useful adhesive compositions having similar adhesive properties to conventional UF and PPF resins. The compositions generally include a protein portion and modifying ingredient portion selected from the group consisting of carboxyl-containing compounds, aldehyde-containing compounds, epoxy group-containing compounds, and mixtures thereof. The composition is preferably prepared at a pH level at or near the isoelectric point of the protein. In other preferred forms, the adhesive composition includes a protein portion and a carboxyl-containing group portion.

The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.

A filter medium capable of removing microorganisms from a fluid such as water. The filter medium includes particles of activated carbon, particles of a substantially insoluble inorganic material having an isoelectric point greater than the fluid being filtered. A low melt index binder, preferably with a melt index of less than about 1 gram per 10 minutes, binds the particles of activated carbon and particles of inorganic material, such that the binder will become tacky at elevated temperatures without becoming sufficiently liquid to substantially wet the particles of activated carbon and inorganic material.

The magnetic tape includes a non-magnetic support; a non-magnetic layer including a non-magnetic powder and a binding agent on the non-magnetic support; and a magnetic layer including a ferromagnetic powder and a binding agent on the non-magnetic layer, in which a total thickness of the non-magnetic layer and the magnetic layer is equal to or smaller than 0.60 μm, an isoelectric point of a surface zeta potential of the magnetic layer is equal to or greater than 5.5, the magnetic layer includes an oxide abrasive, and an average particle diameter of the oxide abrasive obtained from a secondary ion image obtained by irradiating the surface of the magnetic layer with a focused ion beam is 0.04 μm to 0.08 μm.

The invention discloses cathelicidin-BF and a gene and application thereof, which belong to the field of biomedicine. The cathelicidin-BF is straight chain polypeptide and contains thirty amino acid residues, the molecular weight is 3,637.54Da, and the isoelectric point is 11.79. The complete sequence of the cathelicidin-BF is lysine-phenyl alanine-phenyl alanine-arginine-lysine-leucine- lysine-lysine-serine-valine-lysine-lysine-arginine-lactamine-lysine-glutamic acid-phenyl alanine- phenyl alanine-lysine-lysine-proline-arginine-valine-isoleucine-glycin-valine-serine-isoleucine- praline-phenyl alanine. The gene for encoding the cathelicidin-BF consists of 750 ribonucleotides, wherein 484th to 573rd ribonucleotides are used for encoding a mature peptide part. The cathelicidin-BF has small molecular weight, strong sterilization effect, and quick action time, and has quite strong killing function to a plurality of kinds of clinical drug-fast bacteria. In addition, the cathelicidin-BF also has the advantages of broad-spectrum antibiotics, salt independence and so on.

The invention provides a microfluidic apparatus for performing 2-D biomolecular separations. The microfluidic 2-D device may include first and second planar substrates which include at least a first dimension microchannel extending in a first direction and an array of second dimension microchannels extending in a second direction, preferably, orthogonal to the first dimension. The ends of at least some of the microchannels are in fluid communication with a plurality of reservoirs. The substrates may further include a number of microchannels and reservoirs. The reservoirs are in electrical communication with a plurality of electrodes and voltage power sources. The device enables two dimensional separations of proteins and other biomolecules. According to another aspect of the invention, an isoelectric point based separation is enabled in a first dimension, and a size based separation in a second dimension.

The invention discloses a carrier nanometer gold catalyst gold catalyst and relative preparing method. Said invention is formed by Au, Al, and Ti/Si, Ag, Cu, Ce, Fe, or Zn. Wherein, Au is the main active component of catalyst, whose mass percentage is 0.1-4.0%; Al is the carrier of catalyst, whose mass percentage is larger than 90%; Ti or Si is the agent of catalyst carrier, whose mass percentage is 0.01-1.0%; Ag, Cu, Ce, Fe, or Zn is used as the auxiliary active component of catalyst, whose mass percentage is 0.1-5.0%. The invention has the advantages that: the gold is distributed uniformly, and the graininess of attained gold particle can be adjusted easily; the catalyst has high stability; and it can apply the oxide carrier for carrying gold whose isoelectric point pH is less than 6 and made by coprecipitation method. The invention has be used to apply the cyclohexane to prepare the nadone and cyclohexanol, with better activity and selectivity, less used amount and recycle support.

A pharmaceutical composition for nasal administration exhibits an improved bioavailability of a biologically active polypeptide, the active ingredient of the pharmaceutical composition. Specifically, the composition is prepared by uniformly dispersing and embedding a biologically active acidic polypeptide having an isoelectric point of 7 or lower on the surfaces of a polyvalent metal compound carrier with the help of an additive capable of dispersing and embedding the polypeptide on the surfaces of the carrier. The polyvalent metal compound carrier is a metal compound with a valent of 2 or higher that is either insoluble or little soluble in water, examples being aluminum compounds, calcium compounds, magnesium compounds, silicone compounds, iron compounds, and zinc compounds.

A method of forming a structure having selectively placed carbon nanotubes, a method of making charged carbon nanotubes, a bi-functional precursor, and a structure having a high density carbon nanotube layer with minimal bundling. Carbon nanotubes are selectively placed on a substrate having two regions. The first region has an isoelectric point exceeding the second region's isoelectric point. The substrate is immersed in a solution of a bi-functional precursor having anchoring and charged ends. The anchoring end bonds to the first region to form a self-assembled monolayer having a charged end. The substrate with charged monolayer is immersed in a solution of carbon nanotubes having an opposite charge to form a carbon nanotube layer on the self-assembled monolayer. The charged carbon nanotubes are made by functionalization or coating with an ionic surfactant.

A filter medium capable of removing microorganisms from a fluid such as water. The filter medium includes particles of activated carbon, particles of a substantially insoluble inorganic material having an isoelectric point greater than the fluid being filtered. A low melt index binder, preferably with a melt index of less than about 1 gram per 10 minutes, binds the particles of activated carbon and particles of inorganic material, such that the binder will become tacky at elevated temperatures without becoming sufficiently liquid to substantially wet the particles of activated carbon and inorganic material. An antimicrobial material can be incorporated into the filter to prevent biofilm growth. The use of a biocidal material in combination with the high isoelectric point material provides a trap-and-kill mechanism for microorganism removal.

This inventnion relates to a preparation method for high-efficiency prebiotics oat beta-glucan, belonging to the quintessential processing technologies of oat. The said method includes using oat bran as raw materials, crushing, microwave-assisted-extracting, adding amylase and glucoamylase, isoelectric-point-precipitating, centrifugating and separating, concentrating the supernatant, precipitating with ethanol, centrifugating and collecting the precipitation, solving with water, hydrolyzing with beta-glucanase, and spray-drying process to obtain the high-efficiency prebiotics oat beta-glucan with significantly enhanced intestinal and fecal bifidobacteria and actobacillus value-added effect. The method is scientifically and rationally designed, and of great significance in achieving the comprehensive utilization of resources oat and increasing its added value.

The invention relates to a method for preparing a mixed-type nucleotide feed additive from yeast cells and applications of the feed additive, which belong to the technical field of the preparation of nucleotide feed additives from yeast cells. The method comprises the steps: using yeast cells as raw materials and combining a homogenization method and a salt method to break yeast cell walls ; separating the yeast cell walls, protein and other insoluble substances by centrifugation and fractional isoelectric crystallization; specially collecting RNA precipitates at special isoelectric points to obtain wet and crude nucleic acid with the purity of 70 percent; dissolving the wet and crude nucleic acid in water, using high-activity phosphodiesterase from malt roots to carry out a high-efficiency directional enzymatic reaction; directly spraying, drying and crushing the solution after the enzymatic reaction to obtain the mixed-type nucleotide feed additive product comprising the protein content lower than 10 percent and four monosomic nucleotides (AMP, GMP, CMP and UMP) larger than 60 percent. After the feed additive is applied to animal feed, the intestinal absorption function of animals can be notably improved, the growth of the animals is stimulated, and the immune function, the antiviral capability and the anti-stress capability of the animals are improved.

An object of the present invention is to provide a novel protein having the following amino acid sequence altered for specifically and efficiently binding a protein to an immobilization carrier via the carboxy terminus. The protein is used for immobilizing a portion represented by R1-R2 on an immobilization carrier, comprising the amino acid sequence represented by the general formula R1-R2-R3-R4-R5 [wherein:

• • the sequences are oriented from the amino terminal side to the carboxy terminal side;
  • the sequence of the R1 portion is the sequence of a subject protein to be immobilized and contains neither a lysine residue nor a cysteine residue;
  • the sequence of the R2 portion may be absent, but when the sequence of the R2 portion is present, the sequence of the R2 portion is a spacer sequence composed of amino acid residues other than lysine and cysteine residues;
  • the sequence of the R3 portion is composed of two residues of amino acid represented by cysteine-X (where X denotes an amino acid residue other than lysine or cysteine);
  • the sequence of the R4 portion may be absent, but when the sequence of the R4 portion is present, the sequence of the R4 portion contains neither a lysine residue nor a cysteine residue, but contains an acidic amino acid residue capable of acidifying the isoelectric point of the entire protein comprising the amino acid sequence represented by the general formula R1-R2-R3-R4-R5; and
  • the sequence of an R5 portion is an affinity tag sequence for protein purification.

Devices are provided for determining the isoelectric point of a charged analyte, comprising a titration chamber and an electrode chamber. The electrode chamber comprises at least two electrodes, for example, an electrode array. Either or both of the titration chamber and the electrode chamber may have a shaped geometry. The electrodes are operative, in conjunction with the shaped geometry of the chamber(s) where appropriate, to generate an electric field gradient in the titration chamber. Permeable material separates the titration chamber and the electrode chamber. A pH Sensor is located in the titration chamber for obtaining the pH of the first fluid. Certain preferred embodiments further include an analyte band detector for detecting the presence and optionally the location of a focused band of charged solute. Methods are provided for determining the isoelectric point of a charged analyte comprising introducing a carrier fluid comprising a Charge analyte into the titration chamber of a device as just described and applying an electric field gradient to focus the charged analyte into a focused band. The pH of the carrier fluid is incremented or adjusted to shift the location of the focused band of charged analyte, and the pH and location of the focused band of charged analyte are obtained for a plurality of locations and pH's and the isoelectric point is determined from such data.

The magnetic tape includes a non-magnetic support; a magnetic layer including ferromagnetic powder and a binding agent on one surface side of the non-magnetic support; and a back coating layer including non-magnetic powder and a binding agent on the other surface side of the non-magnetic support, in which a thickness of the back coating layer is equal to or smaller than 0.30 μm, and an isoelectric point of a surface zeta potential of the back coating layer is equal to or smaller than 3.0.